| # | Drug | Count |
|---|---|---|
| 0 | VORICONAZOLE | 21 |
| 1 | ADALIMUMAB | 17 |
| 2 | METHOTREXATE SODIUM | 16 |
| 3 | METHOTREXATE | 15 |
| 4 | TACROLIMUS | 15 |
| 5 | LENALIDOMIDE | 14 |
| 6 | PANTOPRAZOLE | 14 |
| 7 | PREDNISONE | 14 |
| 8 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 14 |
| 9 | TACROLIMUS OINTMENT 0.1% | 14 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, METHYLENE BLUE, AND HYOSCYAMINE SULFATE | 1 | 0.0090 |
| 1 | ISAVUCONAZONIUM SULFATE | 10 | 0.0026 |
| 2 | HYDROCORTISONE VALERATE | 1 | 0.0016 |
| 3 | ESTRADIOL VALERATE | 1 | 0.0013 |
| 4 | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | 3 | 0.0011 |
| 5 | ITRACONAZOLE | 13 | 0.0011 |
| 6 | ERDAFITINIB | 1 | 0.0008 |
| 7 | STANDARDIZED SENNA CONCENTRATE AND DOCUSATE SODIUM | 1 | 0.0007 |
| 8 | VORICONAZOLE | 21 | 0.0007 |
| 9 | PLERIXAFOR | 1 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 37 |
| 1 | Azole Antifungal [EPC] | 24 |
| 2 | Tumor Necrosis Factor Blocker [EPC] | 20 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 18 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 15 |
| 5 | Thalidomide Analog [EPC] | 15 |
| 6 | Kinase Inhibitor [EPC] | 12 |
| 7 | Proton Pump Inhibitor [EPC] | 11 |
| 8 | Dihydropyridine Calcium Channel Blocker [EPC] | 10 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 10 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Hematopoietic Stem Cell Mobilizer [EPC] | 1 | 0.0007 |
| 1 | Interleukin-17 Receptor A Antagonist [EPC] | 1 | 0.0005 |
| 2 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 3 | Provitamin D2 Compound [EPC] | 7 | 0.0002 |
| 4 | CD38-directed Cytolytic Antibody [EPC] | 1 | 0.0002 |
| 5 | Azole Antifungal [EPC] | 24 | 0.0002 |
| 6 | Nonergot Dopamine Agonist [EPC] | 2 | 0.0001 |
| 7 | Hedgehog Pathway Inhibitor [EPC] | 1 | 0.0001 |
| 8 | Chloride Channel Activator [EPC] | 1 | 0.0001 |
| 9 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |